In this issue:
Post-infusion CAR T-reg cells identify patients resistive to CD-19 therapy
Outcomes for recurrent mantle cell lymphoma post-ibrutinib therapy
Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma
Six-year results from RELEVANCE
Tafasitamab plus lenalidomide vs systemic therapies for relapsed/refractory DLBCL
Cytokine release syndrome after axicabtagene ciloleucel for DLBCL
CPX-351 yields similar response and survival outcome patients with secondary AML
R-CHOP vs DA-EPOCH-R for double-expressor lymphoma
Suitability for intensive chemotherapy in adults with AML
Please login below to download this issue (PDF)